{
    "abstract": "A number of leishmaniasis vaccine candidates are at various stages of pre-clinical and clinical development. Leishmaniasis is a vector-borne neglected tropical disease (NTD) caused by a protozoan parasite of the genus Leishmania and transmitted to humans by the bite of a sand fly. Visceral leishmaniasis (VL, kala-azar) is a high mortality NTD found mostly in South Asia and East Africa, while cutaneous leishmaniasis (CL) is a disfiguring NTD highly endemic in the Middle East, Central Asia, North Africa, and the Americas. Estimates attribute 50,000 annual deaths and 3.3 million disability-adjusted life years to leishmaniasis. There are only a few approved drug treatments, no prophylactic drug and no vaccine. Ideally, an effective vaccine against leishmaniasis will elicit long-lasting immunity and protect broadly against VL and CL. Vaccines such as Leish-F1, F2 and F3, developed at IDRI and designed based on selected Leishmania antigen epitopes, have been in clinical trials. Other groups, including the Sabin Vaccine Institute in collaboration with the National Institutes of Health are investigating recombinant Leishmania antigens in combination with selected sand fly salivary gland antigens in order to augment host immunity. To date, both VL and CL vaccines have been shown to be cost-effective in economic modeling studies.",
    "author_highlights": [
        {
            "endOffset": 6080,
            "sentence": "Leishmaniasis accrues more than 50,000 deaths and 3.3 million DALYs annually.",
            "startOffset": 6003
        },
        {
            "endOffset": 6148,
            "sentence": "There is currently no licensed vaccine against human leishmaniasis.",
            "startOffset": 6081
        },
        {
            "endOffset": 6222,
            "sentence": "A vaccine will elicit long-lasting immunity and limit chemotherapy usage.",
            "startOffset": 6149
        },
        {
            "endOffset": 6285,
            "sentence": "Recombinant protein-based and DNA-based vaccines are reviewed.",
            "startOffset": 6223
        }
    ],
    "bib_entries": {
        "bib0190": {
            "authors": [
                {
                    "first": "Peter",
                    "initial": "P.",
                    "last": "Hotez"
                }
            ],
            "doi": "10.1377/hlthaff.2011.0317",
            "firstpage": "1080",
            "issn": "02782715",
            "lastpage": "1087",
            "pmid": "21653960",
            "pub_year": 2011,
            "title": "A handful of 'antipoverty' vaccines exist for neglected diseases, but the world's poorest billion people need more",
            "volume": "30"
        },
        "bib0195": {
            "authors": [
                {
                    "first": "Peter J.",
                    "initial": "P.J.",
                    "last": "Hotez"
                }
            ],
            "doi": "10.4269/ajtmh.2012.11-0814",
            "firstpage": "3",
            "issn": "00029637",
            "lastpage": "10",
            "pmid": "22764283",
            "pub_year": 2012,
            "title": "The four horsemen of the apocalypse: Tropical medicine in the fight against plague, death, famine, and war",
            "volume": "87"
        },
        "bib0200": null,
        "bib0205": {
            "authors": [
                {
                    "first": "Peter J.",
                    "initial": "P.J.",
                    "last": "Hotez"
                },
                {
                    "first": "Miriam",
                    "initial": "M.",
                    "last": "Alvarado"
                },
                {
                    "first": "Mar\u00eda Gloria",
                    "initial": "M.G.",
                    "last": "Bas\u00e1\u00f1ez"
                },
                {
                    "first": "Ian",
                    "initial": "I.",
                    "last": "Bolliger"
                },
                {
                    "first": "Rupert",
                    "initial": "R.",
                    "last": "Bourne"
                },
                {
                    "first": "Michel",
                    "initial": "M.",
                    "last": "Boussinesq"
                },
                {
                    "first": "Simon J.",
                    "initial": "S.J.",
                    "last": "Brooker"
                },
                {
                    "first": "Ami Shah",
                    "initial": "A.S.",
                    "last": "Brown"
                },
                {
                    "first": "Geoffrey",
                    "initial": "G.",
                    "last": "Buckle"
                },
                {
                    "first": "Christine M.",
                    "initial": "C.M.",
                    "last": "Budke"
                },
                {
                    "first": "H\u00e9l\u00e8ne",
                    "initial": "H.",
                    "last": "Carabin"
                },
                {
                    "first": "Luc E.",
                    "initial": "L.E.",
                    "last": "Coffeng"
                },
                {
                    "first": "Eric M.",
                    "initial": "E.M.",
                    "last": "F\u00e8vre"
                },
                {
                    "first": "Thomas",
                    "initial": "T.",
                    "last": "F\u00fcrst"
                },
                {
                    "first": "Yara A.",
                    "initial": "Y.A.",
                    "last": "Halasa"
                },
                {
                    "first": "Rashmi",
                    "initial": "R.",
                    "last": "Jasrasaria"
                },
                {
                    "first": "Nicole E.",
                    "initial": "N.E.",
                    "last": "Johns"
                },
                {
                    "first": "Jennifer",
                    "initial": "J.",
                    "last": "Keiser"
                },
                {
                    "first": "Charles H.",
                    "initial": "C.H.",
                    "last": "King"
                },
                {
                    "first": "Rafael",
                    "initial": "R.",
                    "last": "Lozano"
                },
                {
                    "first": "Michele E.",
                    "initial": "M.E.",
                    "last": "Murdoch"
                },
                {
                    "first": "Simon",
                    "initial": "S.",
                    "last": "O'Hanlon"
                },
                {
                    "first": "S\u00e9bastien D.S.",
                    "initial": "S.D.S.",
                    "last": "Pion"
                },
                {
                    "first": "Rachel L.",
                    "initial": "R.L.",
                    "last": "Pullan"
                },
                {
                    "first": "Kapa D.",
                    "initial": "K.D.",
                    "last": "Ramaiah"
                },
                {
                    "first": "Thomas",
                    "initial": "T.",
                    "last": "Roberts"
                },
                {
                    "first": "Donald S.",
                    "initial": "D.S.",
                    "last": "Shepard"
                },
                {
                    "first": "Jennifer L.",
                    "initial": "J.L.",
                    "last": "Smith"
                },
                {
                    "first": "Wilma A.",
                    "initial": "W.A.",
                    "last": "Stolk"
                },
                {
                    "first": "Eduardo A.",
                    "initial": "E.A.",
                    "last": "Undurraga"
                },
                {
                    "first": "J\u00fcrg",
                    "initial": "J.",
                    "last": "Utzinger"
                },
                {
                    "first": "Mengru",
                    "initial": "M.",
                    "last": "Wang"
                },
                {
                    "first": "Christopher J.L.",
                    "initial": "C.J.L.",
                    "last": "Murray"
                },
                {
                    "first": "Mohsen",
                    "initial": "M.",
                    "last": "Naghavi"
                }
            ],
            "doi": "10.1371/journal.pntd.0002865",
            "issn": "19352727",
            "pub_year": 2014,
            "title": "The Global Burden of Disease Study 2010: Interpretation and Implications for the Neglected Tropical Diseases",
            "volume": "8"
        },
        "bib0210": null,
        "bib0215": {
            "authors": [
                {
                    "first": "A. M.",
                    "initial": "A.M.",
                    "last": "De Vasquez"
                },
                {
                    "first": "R. E.",
                    "initial": "R.E.",
                    "last": "Saenz"
                },
                {
                    "first": "J. L.",
                    "initial": "J.L.",
                    "last": "Petersen"
                },
                {
                    "first": "H. A.",
                    "initial": "H.A.",
                    "last": "Christensen"
                },
                {
                    "first": "C. M.",
                    "initial": "C.M.",
                    "last": "Johnson"
                }
            ],
            "doi": "10.4269/ajtmh.1990.43.619",
            "firstpage": "619",
            "issn": "00029637",
            "lastpage": "622",
            "pmid": "2267966",
            "pub_year": 1990,
            "title": "Leishmania mexicana complex: Human infections in the Republic of Panama",
            "volume": "43"
        },
        "bib0220": null,
        "bib0225": {
            "authors": [
                {
                    "first": "E. E.",
                    "initial": "E.E.",
                    "last": "Zijlstra"
                },
                {
                    "first": "A. M.",
                    "initial": "A.M.",
                    "last": "El-Hassan"
                }
            ],
            "firstpage": "S1/58",
            "issn": "00359203",
            "pmid": "11370250",
            "pub_year": 2001,
            "title": "Leishmaniasis in Sudan 3. Visceral ieishmaniasis",
            "volume": "95"
        },
        "bib0230": {
            "authors": [
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Seaman"
                },
                {
                    "first": "A. J.",
                    "initial": "A.J.",
                    "last": "Mercer"
                },
                {
                    "first": "E.",
                    "initial": "E.",
                    "last": "Sondorp"
                }
            ],
            "doi": "10.1093/ije/25.4.862",
            "firstpage": "862",
            "issn": "03005771",
            "lastpage": "871",
            "pmid": "8921468",
            "pub_year": 1996,
            "title": "The epidemic of visceral leishmaniasis in Western Upper Nile, southern Sudan: Course and impact from 1984 to 1994",
            "volume": "25"
        },
        "bib0235": null,
        "bib0240": null,
        "bib0245": {
            "authors": [
                {
                    "first": "Coreen M.",
                    "initial": "C.M.",
                    "last": "Beaumier"
                },
                {
                    "first": "Portia M.",
                    "initial": "P.M.",
                    "last": "Gillespie"
                },
                {
                    "first": "Peter J.",
                    "initial": "P.J.",
                    "last": "Hotez"
                },
                {
                    "first": "Maria Elena",
                    "initial": "M.E.",
                    "last": "Bottazzi"
                }
            ],
            "doi": "10.1016/j.trsl.2013.03.006",
            "firstpage": "144",
            "issn": "19315244",
            "lastpage": "155",
            "pub_year": 2013,
            "title": "New vaccines for neglected parasitic diseases and dengue",
            "volume": "162"
        },
        "bib0250": {
            "authors": [
                {
                    "first": "Michael",
                    "initial": "M.",
                    "last": "Coleman"
                },
                {
                    "first": "Geraldine M.",
                    "initial": "G.M.",
                    "last": "Foster"
                },
                {
                    "first": "Rinki",
                    "initial": "R.",
                    "last": "Deb"
                },
                {
                    "first": "Rudra Pratap",
                    "initial": "R.P.",
                    "last": "Singh"
                },
                {
                    "first": "Hanafy M.",
                    "initial": "H.M.",
                    "last": "Ismail"
                },
                {
                    "first": "Pushkar",
                    "initial": "P.",
                    "last": "Shivam"
                },
                {
                    "first": "Ayan Kumar",
                    "initial": "A.K.",
                    "last": "Ghosh"
                },
                {
                    "first": "Sophie",
                    "initial": "S.",
                    "last": "Dunkley"
                },
                {
                    "first": "Vijay",
                    "initial": "V.",
                    "last": "Kumar"
                },
                {
                    "first": "Marlize",
                    "initial": "M.",
                    "last": "Coleman"
                },
                {
                    "first": "Janet",
                    "initial": "J.",
                    "last": "Hemingway"
                },
                {
                    "first": "Mark J.I.",
                    "initial": "M.J.I.",
                    "last": "Paine"
                },
                {
                    "first": "Pradeep",
                    "initial": "P.",
                    "last": "Das"
                }
            ],
            "doi": "10.1073/pnas.1507782112",
            "firstpage": "8573",
            "issn": "00278424",
            "lastpage": "8578",
            "pmid": "26124110",
            "pub_year": 2015,
            "title": "DDT-based indoor residual spraying suboptimal for visceral leishmaniasis elimination in India",
            "volume": "112"
        },
        "bib0255": {
            "authors": [
                {
                    "first": "Malcolm S.",
                    "initial": "M.S.",
                    "last": "Duthie"
                },
                {
                    "first": "Vanitha S.",
                    "initial": "V.S.",
                    "last": "Raman"
                },
                {
                    "first": "Franco M.",
                    "initial": "F.M.",
                    "last": "Piazza"
                },
                {
                    "first": "Steven G.",
                    "initial": "S.G.",
                    "last": "Reed"
                }
            ],
            "doi": "10.1016/j.vaccine.2011.11.005",
            "firstpage": "134",
            "issn": "0264410X",
            "lastpage": "141",
            "pmid": "22085553",
            "pub_year": 2012,
            "title": "The development and clinical evaluation of second-generation leishmaniasis vaccines",
            "volume": "30"
        },
        "bib0260": {
            "authors": [
                {
                    "first": "Iraci D.",
                    "initial": "I.D.",
                    "last": "Lima"
                },
                {
                    "first": "Jose W.",
                    "initial": "J.W.",
                    "last": "Queiroz"
                },
                {
                    "first": "Henio G.",
                    "initial": "H.G.",
                    "last": "Lacerda"
                },
                {
                    "first": "Paula V.S.",
                    "initial": "P.V.S.",
                    "last": "Queiroz"
                },
                {
                    "first": "Nubia N.",
                    "initial": "N.N.",
                    "last": "Pontes"
                },
                {
                    "first": "James D.A.",
                    "initial": "J.D.A.",
                    "last": "Barbosa"
                },
                {
                    "first": "Daniella R.",
                    "initial": "D.R.",
                    "last": "Martins"
                },
                {
                    "first": "Jason L.",
                    "initial": "J.L.",
                    "last": "Weirather"
                },
                {
                    "first": "Richard D.",
                    "initial": "R.D.",
                    "last": "Pearson"
                },
                {
                    "first": "Mary E.",
                    "initial": "M.E.",
                    "last": "Wilson"
                },
                {
                    "first": "Selma M.B.",
                    "initial": "S.M.B.",
                    "last": "Jeronimo"
                }
            ],
            "doi": "10.4269/ajtmh.2012.10-0492",
            "firstpage": "99",
            "issn": "00029637",
            "lastpage": "107",
            "pmid": "22232458",
            "pub_year": 2012,
            "title": "Leishmania infantum chagasi in Northeastern Brazil: Asymptomatic infection at the urban perimeter",
            "volume": "86"
        },
        "bib0265": {
            "authors": [
                {
                    "first": "Kristina M.",
                    "initial": "K.M.",
                    "last": "Bacon"
                },
                {
                    "first": "Peter J.",
                    "initial": "P.J.",
                    "last": "Hotez"
                },
                {
                    "first": "Stephanie D.",
                    "initial": "S.D.",
                    "last": "Kruchten"
                },
                {
                    "first": "Shaden",
                    "initial": "S.",
                    "last": "Kamhawi"
                },
                {
                    "first": "Maria Elena",
                    "initial": "M.E.",
                    "last": "Bottazzi"
                },
                {
                    "first": "Jesus G.",
                    "initial": "J.G.",
                    "last": "Valenzuela"
                },
                {
                    "first": "Bruce Y.",
                    "initial": "B.Y.",
                    "last": "Lee"
                }
            ],
            "doi": "10.1016/j.vaccine.2012.11.032",
            "firstpage": "480",
            "issn": "0264410X",
            "lastpage": "486",
            "pmid": "23176979",
            "pub_year": 2013,
            "title": "The potential economic value of a cutaneous leishmaniasis vaccine in seven endemic countries in the Americas",
            "volume": "31"
        },
        "bib0270": {
            "authors": [
                {
                    "first": "Bruce Y.",
                    "initial": "B.Y.",
                    "last": "Lee"
                },
                {
                    "first": "Kristina M.",
                    "initial": "K.M.",
                    "last": "Bacon"
                },
                {
                    "first": "Mirat",
                    "initial": "M.",
                    "last": "Shah"
                },
                {
                    "first": "Sarah Beth",
                    "initial": "S.B.",
                    "last": "Kitchen"
                },
                {
                    "first": "Diana L.",
                    "initial": "D.L.",
                    "last": "Connor"
                },
                {
                    "first": "Rachel B.",
                    "initial": "R.B.",
                    "last": "Slayton"
                }
            ],
            "doi": "10.4269/ajtmh.2012.10-0415",
            "firstpage": "417",
            "issn": "00029637",
            "lastpage": "425",
            "pmid": "22403311",
            "pub_year": 2012,
            "title": "The economic value of a visceral leishmaniasis vaccine in Bihar State, India",
            "volume": "86"
        },
        "bib0275": {
            "authors": [
                {
                    "first": "Rajeev",
                    "initial": "R.",
                    "last": "Nagill"
                },
                {
                    "first": "Sukhbir",
                    "initial": "S.",
                    "last": "Kaur"
                }
            ],
            "doi": "10.1016/j.intimp.2011.05.008",
            "firstpage": "1464",
            "issn": "15675769",
            "lastpage": "1488",
            "pmid": "21616175",
            "pub_year": 2011,
            "title": "Vaccine candidates for leishmaniasis: A review",
            "volume": "11"
        },
        "bib0280": {
            "authors": [
                {
                    "first": "Jorge",
                    "initial": "J.",
                    "last": "Alvar"
                },
                {
                    "first": "Simon L.",
                    "initial": "S.L.",
                    "last": "Croft"
                },
                {
                    "first": "Paul",
                    "initial": "P.",
                    "last": "Kaye"
                },
                {
                    "first": "Ali",
                    "initial": "A.",
                    "last": "Khamesipour"
                },
                {
                    "first": "Shyam",
                    "initial": "S.",
                    "last": "Sundar"
                },
                {
                    "first": "Steven G.",
                    "initial": "S.G.",
                    "last": "Reed"
                }
            ],
            "doi": "10.1016/j.vaccine.2012.11.080",
            "firstpage": "B244",
            "issn": "0264410X",
            "lastpage": "B249",
            "pmid": "23598489",
            "pub_year": 2013,
            "title": "Case study for a vaccine against leishmaniasis",
            "volume": "31"
        },
        "bib0285": {
            "authors": [
                {
                    "first": "Iraj",
                    "initial": "I.",
                    "last": "Sharifi"
                },
                {
                    "first": "Ali Reza",
                    "initial": "A.R.",
                    "last": "Fekri"
                },
                {
                    "first": "Mohammad Reza",
                    "initial": "M.R.",
                    "last": "Aflatonian"
                },
                {
                    "first": "Ali",
                    "initial": "A.",
                    "last": "Khamesipour"
                },
                {
                    "first": "Abolhassan",
                    "initial": "A.",
                    "last": "Nadim"
                },
                {
                    "first": "Mohammad Reza",
                    "initial": "M.R.",
                    "last": "Ahmadi Mousavi"
                },
                {
                    "first": "Ali Z.",
                    "initial": "A.Z.",
                    "last": "Momeni"
                },
                {
                    "first": "Yahya",
                    "initial": "Y.",
                    "last": "Dowlati"
                },
                {
                    "first": "Tore",
                    "initial": "T.",
                    "last": "Godal"
                },
                {
                    "first": "Fabio",
                    "initial": "F.",
                    "last": "Zicker"
                },
                {
                    "first": "Peter G.",
                    "initial": "P.G.",
                    "last": "Smith"
                },
                {
                    "first": "Farrokh",
                    "initial": "F.",
                    "last": "Modabber"
                }
            ],
            "doi": "10.1016/S0140-6736(98)09552-X",
            "firstpage": "1540",
            "issn": "01406736",
            "lastpage": "1543",
            "pmid": "10326536",
            "pub_year": 1998,
            "title": "Randomised vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran",
            "volume": "351"
        },
        "bib0290": {
            "authors": [
                {
                    "first": "Vanitha S.",
                    "initial": "V.S.",
                    "last": "Raman"
                },
                {
                    "first": "Malcolm S.",
                    "initial": "M.S.",
                    "last": "Duthie"
                },
                {
                    "first": "Christopher B.",
                    "initial": "C.B.",
                    "last": "Fox"
                },
                {
                    "first": "Greg",
                    "initial": "G.",
                    "last": "Matlashewski"
                },
                {
                    "first": "Steven G.",
                    "initial": "S.G.",
                    "last": "Reed"
                }
            ],
            "doi": "10.3389/fimmu.2012.00144",
            "issn": "16643224",
            "pub_year": 2012,
            "title": "Adjuvants for Leishmania vaccines: From models to clinical application",
            "volume": "3"
        },
        "bib0295": null,
        "bib0300": {
            "authors": [
                {
                    "first": "Sylvie",
                    "initial": "S.",
                    "last": "Bertholet"
                },
                {
                    "first": "Yasuyuki",
                    "initial": "Y.",
                    "last": "Goto"
                },
                {
                    "first": "Lauren",
                    "initial": "L.",
                    "last": "Carter"
                },
                {
                    "first": "Ajay",
                    "initial": "A.",
                    "last": "Bhatia"
                },
                {
                    "first": "Randall F.",
                    "initial": "R.F.",
                    "last": "Howard"
                },
                {
                    "first": "Darrick",
                    "initial": "D.",
                    "last": "Carter"
                },
                {
                    "first": "Rhea N.",
                    "initial": "R.N.",
                    "last": "Coler"
                },
                {
                    "first": "Thomas S.",
                    "initial": "T.S.",
                    "last": "Vedvick"
                },
                {
                    "first": "Steven G.",
                    "initial": "S.G.",
                    "last": "Reed"
                }
            ],
            "doi": "10.1016/j.vaccine.2009.09.066",
            "firstpage": "7036",
            "issn": "0264410X",
            "lastpage": "7045",
            "pmid": "19786136",
            "pub_year": 2009,
            "title": "Optimized subunit vaccine protects against experimental leishmaniasis",
            "volume": "27"
        },
        "bib0305": {
            "authors": [
                {
                    "first": "Rhea N.",
                    "initial": "R.N.",
                    "last": "Coler"
                },
                {
                    "first": "Malcolm S.",
                    "initial": "M.S.",
                    "last": "Duthie"
                },
                {
                    "first": "Kimberly A.",
                    "initial": "K.A.",
                    "last": "Hofmeyer"
                },
                {
                    "first": "Jeffery",
                    "initial": "J.",
                    "last": "Guderian"
                },
                {
                    "first": "Lakshmi",
                    "initial": "L.",
                    "last": "Jayashankar"
                },
                {
                    "first": "Julie",
                    "initial": "J.",
                    "last": "Vergara"
                },
                {
                    "first": "Tom",
                    "initial": "T.",
                    "last": "Rolf"
                },
                {
                    "first": "Ayesha",
                    "initial": "A.",
                    "last": "Misquith"
                },
                {
                    "first": "John D.",
                    "initial": "J.D.",
                    "last": "Laurance"
                },
                {
                    "first": "Vanitha S.",
                    "initial": "V.S.",
                    "last": "Raman"
                },
                {
                    "first": "H. Remy",
                    "initial": "H.R.",
                    "last": "Bailor"
                },
                {
                    "first": "Natasha Dubois",
                    "initial": "N.D.",
                    "last": "Cauwelaert"
                },
                {
                    "first": "Steven J.",
                    "initial": "S.J.",
                    "last": "Reed"
                },
                {
                    "first": "Aarthy",
                    "initial": "A.",
                    "last": "Vallur"
                },
                {
                    "first": "Michelle",
                    "initial": "M.",
                    "last": "Favila"
                },
                {
                    "first": "Mark T.",
                    "initial": "M.T.",
                    "last": "Orr"
                },
                {
                    "first": "Jill",
                    "initial": "J.",
                    "last": "Ashman"
                },
                {
                    "first": "Prakash",
                    "initial": "P.",
                    "last": "Ghosh"
                },
                {
                    "first": "Dinesh",
                    "initial": "D.",
                    "last": "Mondal"
                },
                {
                    "first": "Steven G.",
                    "initial": "S.G.",
                    "last": "Reed"
                }
            ],
            "doi": "10.1038/cti.2015.6",
            "issn": "20500068",
            "pub_year": 2015,
            "title": "From mouse to man: safety, immunogenicity and efficacy of a candidate leishmaniasis vaccine LEISH-F3+GLA-SE",
            "volume": "4"
        },
        "bib0310": {
            "authors": [
                {
                    "first": "Keerti",
                    "initial": "K.",
                    "last": "Jain"
                },
                {
                    "first": "N. K.",
                    "initial": "N.K.",
                    "last": "Jain"
                }
            ],
            "doi": "10.1016/j.jim.2015.03.017",
            "firstpage": "1",
            "issn": "00221759",
            "lastpage": "12",
            "pmid": "25858230",
            "pub_year": 2015,
            "title": "Vaccines for visceral leishmaniasis: A review",
            "volume": "422"
        },
        "bib0315": {
            "authors": [
                {
                    "first": "Maha",
                    "initial": "M.",
                    "last": "Abdeladhim"
                },
                {
                    "first": "Shaden",
                    "initial": "S.",
                    "last": "Kamhawi"
                },
                {
                    "first": "Jesus G.",
                    "initial": "J.G.",
                    "last": "Valenzuela"
                }
            ],
            "doi": "10.1016/j.meegid.2014.07.028",
            "firstpage": "691",
            "issn": "15671348",
            "lastpage": "703",
            "pmid": "25117872",
            "pub_year": 2014,
            "title": "What's behind a sand fly bite? The profound effect of sand fly saliva on host hemostasis, inflammation and immunity",
            "volume": "28"
        },
        "bib0320": {
            "authors": [
                {
                    "first": "Shaden",
                    "initial": "S.",
                    "last": "Kamhawi"
                },
                {
                    "first": "Hamide",
                    "initial": "H.",
                    "last": "Aslan"
                },
                {
                    "first": "Jesus G.",
                    "initial": "J.G.",
                    "last": "Valenzuela"
                }
            ],
            "doi": "10.3389/fpubh.2014.00099",
            "issn": "22962565",
            "pub_year": 2014,
            "title": "Vector saliva in vaccines for visceral leishmaniasis: A brief encounter of high consequence?",
            "volume": "2"
        },
        "bib0325": {
            "authors": [
                {
                    "first": "Fabiano",
                    "initial": "F.",
                    "last": "Oliveira"
                },
                {
                    "first": "Edgar",
                    "initial": "E.",
                    "last": "Rowton"
                },
                {
                    "first": "Hamide",
                    "initial": "H.",
                    "last": "Aslan"
                },
                {
                    "first": "Regis",
                    "initial": "R.",
                    "last": "Gomes"
                },
                {
                    "first": "Philip A.",
                    "initial": "P.A.",
                    "last": "Castrovinci"
                },
                {
                    "first": "Patricia H.",
                    "initial": "P.H.",
                    "last": "Alvarenga"
                },
                {
                    "first": "Maha",
                    "initial": "M.",
                    "last": "Abdeladhim"
                },
                {
                    "first": "Clarissa",
                    "initial": "C.",
                    "last": "Teixeira"
                },
                {
                    "first": "Claudio",
                    "initial": "C.",
                    "last": "Meneses"
                },
                {
                    "first": "Lindsey T.",
                    "initial": "L.T.",
                    "last": "Kleeman"
                },
                {
                    "first": "Anderson B.",
                    "initial": "A.B.",
                    "last": "Guimar\u00e3es-Costa"
                },
                {
                    "first": "Tobin E.",
                    "initial": "T.E.",
                    "last": "Rowland"
                },
                {
                    "first": "Dana",
                    "initial": "D.",
                    "last": "Gilmore"
                },
                {
                    "first": "Seydou",
                    "initial": "S.",
                    "last": "Doumbia"
                },
                {
                    "first": "Steven G.",
                    "initial": "S.G.",
                    "last": "Reed"
                },
                {
                    "first": "Phillip G.",
                    "initial": "P.G.",
                    "last": "Lawyer"
                },
                {
                    "first": "John F.",
                    "initial": "J.F.",
                    "last": "Andersen"
                },
                {
                    "first": "Shaden",
                    "initial": "S.",
                    "last": "Kamhawi"
                },
                {
                    "first": "Jesus G.",
                    "initial": "J.G.",
                    "last": "Valenzuela"
                }
            ],
            "doi": "10.1126/scitranslmed.aaa3043",
            "issn": "19466234",
            "pmid": "26041707",
            "pub_year": 2015,
            "title": "A sand fly salivary protein vaccine shows efficacy against vector-transmitted cutaneous leishmaniasis in nonhuman primates",
            "volume": "7"
        },
        "bib0330": {
            "authors": [
                {
                    "first": "Jaya",
                    "initial": "J.",
                    "last": "Chakravarty"
                },
                {
                    "first": "Subodh",
                    "initial": "S.",
                    "last": "Kumar"
                },
                {
                    "first": "Sonali",
                    "initial": "S.",
                    "last": "Trivedi"
                },
                {
                    "first": "Vijay K.",
                    "initial": "V.K.",
                    "last": "Rai"
                },
                {
                    "first": "Anup",
                    "initial": "A.",
                    "last": "Singh"
                },
                {
                    "first": "Jill A.",
                    "initial": "J.A.",
                    "last": "Ashman"
                },
                {
                    "first": "Elsa M.",
                    "initial": "E.M.",
                    "last": "Laughlin"
                },
                {
                    "first": "Rhea N.",
                    "initial": "R.N.",
                    "last": "Coler"
                },
                {
                    "first": "Stuart J.",
                    "initial": "S.J.",
                    "last": "Kahn"
                },
                {
                    "first": "Anna Marie",
                    "initial": "A.M.",
                    "last": "Beckmann"
                },
                {
                    "first": "Karen D.",
                    "initial": "K.D.",
                    "last": "Cowgill"
                },
                {
                    "first": "Steven G.",
                    "initial": "S.G.",
                    "last": "Reed"
                },
                {
                    "first": "Shyam",
                    "initial": "S.",
                    "last": "Sundar"
                },
                {
                    "first": "Franco M.",
                    "initial": "F.M.",
                    "last": "Piazza"
                }
            ],
            "doi": "10.1016/j.vaccine.2011.02.096",
            "firstpage": "3531",
            "issn": "0264410X",
            "lastpage": "3537",
            "pmid": "21414377",
            "pub_year": 2011,
            "title": "A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine for use in the prevention of visceral leishmaniasis",
            "volume": "29"
        },
        "bib0335": {
            "authors": [
                {
                    "first": "Evaldo",
                    "initial": "E.",
                    "last": "Nascimento"
                },
                {
                    "first": "Demetrios F.",
                    "initial": "D.F.",
                    "last": "Fernandes"
                },
                {
                    "first": "Edva P.",
                    "initial": "E.P.",
                    "last": "Vieira"
                },
                {
                    "first": "Antonio",
                    "initial": "A.",
                    "last": "Campos-Neto"
                },
                {
                    "first": "Jill A.",
                    "initial": "J.A.",
                    "last": "Ashman"
                },
                {
                    "first": "Fabiana P.",
                    "initial": "F.P.",
                    "last": "Alves"
                },
                {
                    "first": "Rhea N.",
                    "initial": "R.N.",
                    "last": "Coler"
                },
                {
                    "first": "Lisa Y.",
                    "initial": "L.Y.",
                    "last": "Bogatzki"
                },
                {
                    "first": "Stuart J.",
                    "initial": "S.J.",
                    "last": "Kahn"
                },
                {
                    "first": "Anna Marie",
                    "initial": "A.M.",
                    "last": "Beckmann"
                },
                {
                    "first": "Samuel O.",
                    "initial": "S.O.",
                    "last": "Pine"
                },
                {
                    "first": "Karen D.",
                    "initial": "K.D.",
                    "last": "Cowgill"
                },
                {
                    "first": "Steven G.",
                    "initial": "S.G.",
                    "last": "Reed"
                },
                {
                    "first": "Franco M.",
                    "initial": "F.M.",
                    "last": "Piazza"
                }
            ],
            "doi": "10.1016/j.vaccine.2010.07.063",
            "firstpage": "6581",
            "issn": "0264410X",
            "lastpage": "6587",
            "pmid": "20688040",
            "pub_year": 2010,
            "title": "A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine when used in combination with meglumine antimoniate for the treatment of cutaneous leishmaniasis",
            "volume": "28"
        },
        "bib0340": {
            "authors": [
                {
                    "first": "Alejandro",
                    "initial": "A.",
                    "last": "Llanos-Cuentas"
                },
                {
                    "first": "Wessmark",
                    "initial": "W.",
                    "last": "Calder\u00f3n"
                },
                {
                    "first": "Mar\u00eda",
                    "initial": "M.",
                    "last": "Cruz"
                },
                {
                    "first": "Jill A.",
                    "initial": "J.A.",
                    "last": "Ashman"
                },
                {
                    "first": "Fabiana P.",
                    "initial": "F.P.",
                    "last": "Alves"
                },
                {
                    "first": "Rhea N.",
                    "initial": "R.N.",
                    "last": "Coler"
                },
                {
                    "first": "Lisa Y.",
                    "initial": "L.Y.",
                    "last": "Bogatzki"
                },
                {
                    "first": "Sylvie",
                    "initial": "S.",
                    "last": "Bertholet"
                },
                {
                    "first": "Elsa M.",
                    "initial": "E.M.",
                    "last": "Laughlin"
                },
                {
                    "first": "Stuart J.",
                    "initial": "S.J.",
                    "last": "Kahn"
                },
                {
                    "first": "Anna Marie",
                    "initial": "A.M.",
                    "last": "Beckmann"
                },
                {
                    "first": "Karen D.",
                    "initial": "K.D.",
                    "last": "Cowgill"
                },
                {
                    "first": "Steven G.",
                    "initial": "S.G.",
                    "last": "Reed"
                },
                {
                    "first": "Franco M.",
                    "initial": "F.M.",
                    "last": "Piazza"
                }
            ],
            "doi": "10.1016/j.vaccine.2010.08.092",
            "firstpage": "7427",
            "issn": "0264410X",
            "lastpage": "7435",
            "pmid": "20851080",
            "pub_year": 2010,
            "title": "A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine when used in combination with sodium stibogluconate for the treatment of mucosal leishmaniasis",
            "volume": "28"
        },
        "bib0345": null,
        "bib0350": null,
        "bib0355": null,
        "bib0360": null
    },
    "body_text": [
        {
            "endOffset": 19717,
            "parents": [],
            "refoffsets": {
                "bib0245": {
                    "endOffset": 19716,
                    "startOffset": 19709
                },
                "bib0350": {
                    "endOffset": 19716,
                    "startOffset": 19709
                }
            },
            "secId": "sec0030",
            "sentence": "IDRI is currently in a phase I trial with their new LEISH-F3 vaccine, in healthy adult volunteers in Washington, USA [12,33].",
            "startOffset": 19592,
            "title": "Status of vaccine R&D activities"
        },
        {
            "endOffset": 15932,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Overview of current efforts"
                }
            ],
            "secId": "sec0020",
            "sentence": "As mentioned earlier, the evidence that parasite control and protective immunity is dependent on TH1 immune responses has been helpful for research in this area.",
            "startOffset": 15771,
            "title": "General approaches to vaccine development for this disease for low and middle income country markets"
        },
        {
            "endOffset": 8149,
            "parents": [],
            "refoffsets": {
                "bib0190": {
                    "endOffset": 8148,
                    "startOffset": 8143
                },
                "bib0195": {
                    "endOffset": 8148,
                    "startOffset": 8143
                },
                "bib0200": {
                    "endOffset": 8148,
                    "startOffset": 8143
                }
            },
            "secId": "sec0005",
            "sentence": "It is estimated that 1.3 million new cases occur annually, adding to the 10\u201312 million cases found globally [1\u20133].",
            "startOffset": 8035,
            "title": "About the disease and pathogen"
        },
        {
            "endOffset": 7936,
            "parents": [],
            "secId": "sec0005",
            "sentence": "The disease is vector borne and transmitted to humans by the bite of a sand fly.",
            "startOffset": 7856,
            "title": "About the disease and pathogen"
        },
        {
            "endOffset": 18557,
            "parents": [],
            "refoffsets": {
                "bib0245": {
                    "endOffset": 18556,
                    "startOffset": 18549
                },
                "bib0330": {
                    "endOffset": 18556,
                    "startOffset": 18549
                }
            },
            "secId": "sec0030",
            "sentence": "Phase I trials with this vaccine were completed in the United States, Colombia, Brazil, Peru and India, and demonstrated safety and immunogenicity in endemic and non-endemic populations [12,29].",
            "startOffset": 18363,
            "title": "Status of vaccine R&D activities"
        },
        {
            "endOffset": 9319,
            "parents": [],
            "refoffsets": {
                "bib0210": {
                    "endOffset": 8641,
                    "startOffset": 8638
                },
                "bib0215": {
                    "endOffset": 8953,
                    "startOffset": 8950
                },
                "bib0220": {
                    "endOffset": 9318,
                    "startOffset": 9315
                }
            },
            "secId": "sec0005",
            "sentence": "A more recent update from GBD 2013 indicates that 62,500 people died from the visceral form of leishmaniasis in 2013 [5], Leishmaniasis has a variety of clinical manifestations, classified according to the clinical syndromes caused by individual species of the parasite: Cutaneous Leishmaniasis (CL) with its disfiguring skin ulcers, caused mostly by the Leishmania mexicana and Leishmania braziliensis complexes in the Americas [6] and Leishmania major and Leishmania tropica in the Middle East and Central Asia; Visceral Leishmaniasis (VL), caused by the Leishmania donovani complex, as well as Leishmania infantum and Leishmania chagasi, also responsible for Post-Kala-azar Dermal Leishmaniasis (PKDL); Mucosal/Mucocutaneous Leishmaniasis (MCL); a severe and chronic mucocutaneous infection [7].",
            "startOffset": 8521,
            "title": "About the disease and pathogen"
        },
        {
            "endOffset": 10188,
            "parents": [],
            "refoffsets": {
                "bib0200": {
                    "endOffset": 10187,
                    "startOffset": 10184
                }
            },
            "secId": "sec0005",
            "sentence": "Leishmaniasis affects the poorest people living around the Mediterranean Basin, in South-East Asia, East Africa, Afro-Eurasia, and the Americas, and periodic epidemics are known to occur in these areas (Ethiopia [2005, 2006], Kenya [2008], and Sudan [2009\u20132011]) [3].",
            "startOffset": 9921,
            "title": "About the disease and pathogen"
        },
        {
            "endOffset": 12690,
            "parents": [],
            "refoffsets": {
                "bib0265": {
                    "endOffset": 12689,
                    "startOffset": 12682
                },
                "bib0270": {
                    "endOffset": 12689,
                    "startOffset": 12682
                }
            },
            "secId": "sec0005",
            "sentence": "For VL even a vaccine that provides protection for only five years at 50% efficacy would still be cost effective as compared to current treatments which has also been confirmed via a similar study for VL in Bihar State [16,17].",
            "startOffset": 12463,
            "title": "About the disease and pathogen"
        },
        {
            "endOffset": 15770,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Overview of current efforts"
                }
            ],
            "refoffsets": {
                "bib0245": {
                    "endOffset": 15769,
                    "startOffset": 15762
                },
                "bib0255": {
                    "endOffset": 15769,
                    "startOffset": 15762
                }
            },
            "secId": "sec0020",
            "sentence": "Currently, the emphasis of the so-called second generation vaccines is on the subunit/recombinant protein approach using a range of adjuvants to augment the immunogenicity of the selected antigens [12,14].",
            "startOffset": 15565,
            "title": "General approaches to vaccine development for this disease for low and middle income country markets"
        },
        {
            "endOffset": 11175,
            "parents": [],
            "refoffsets": {
                "bib0200": {
                    "endOffset": 11174,
                    "startOffset": 11168
                },
                "bib0245": {
                    "endOffset": 11174,
                    "startOffset": 11168
                }
            },
            "secId": "sec0005",
            "sentence": "However, factors such as high costs, toxicity, and long-term and complicated regimens compromise most chemotherapeutic options, though the development of new therapies may start to alleviate these concerns [3,12].",
            "startOffset": 10962,
            "title": "About the disease and pathogen"
        },
        {
            "endOffset": 16480,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Overview of current efforts"
                }
            ],
            "secId": "sec0020",
            "sentence": "Alternatively, antigens delivered as DNA formulations are also being tested.",
            "startOffset": 16404,
            "title": "General approaches to vaccine development for this disease for low and middle income country markets"
        },
        {
            "endOffset": 18168,
            "parents": [],
            "secId": "sec0030",
            "sentence": "LEISH-F1, is a fusion protein made up of three polypeptides in tandem, formulated with monophosphoryl lipid A-stable emulsion (MPL-SE).",
            "startOffset": 18033,
            "title": "Status of vaccine R&D activities"
        },
        {
            "endOffset": 15564,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Overview of current efforts"
                }
            ],
            "refoffsets": {
                "bib0245": {
                    "endOffset": 15563,
                    "startOffset": 15553
                },
                "bib0255": {
                    "endOffset": 15563,
                    "startOffset": 15553
                },
                "bib0305": {
                    "endOffset": 15563,
                    "startOffset": 15553
                }
            },
            "secId": "sec0020",
            "sentence": "These vaccines have focused on CL and VL with inconsistent clinical results [12,14,24].",
            "startOffset": 15477,
            "title": "General approaches to vaccine development for this disease for low and middle income country markets"
        },
        {
            "endOffset": 13810,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Overview of current efforts"
                }
            ],
            "secId": "sec0015",
            "sentence": "Leishmanization vaccines have been developed and were in use in various countries (former Soviet Union, Central Asia, Israel, and Iran) and remain the only group of leishmaniasis vaccines to show efficacy in humans.",
            "startOffset": 13595,
            "title": "Biological feasibility for vaccine development"
        },
        {
            "endOffset": 8034,
            "parents": [],
            "secId": "sec0005",
            "sentence": "Roughly 350 million people are at risk, living in areas that are endemic to Leishmania parasites.",
            "startOffset": 7937,
            "title": "About the disease and pathogen"
        },
        {
            "endOffset": 9695,
            "parents": [],
            "secId": "sec0005",
            "sentence": "The disease can have a case-fatality rate of up to 100% in the absence of treatment.",
            "startOffset": 9611,
            "title": "About the disease and pathogen"
        },
        {
            "endOffset": 10463,
            "parents": [],
            "refoffsets": {
                "bib0225": {
                    "endOffset": 10351,
                    "startOffset": 10346
                },
                "bib0230": {
                    "endOffset": 10351,
                    "startOffset": 10346
                },
                "bib0235": {
                    "endOffset": 10462,
                    "startOffset": 10458
                }
            },
            "secId": "sec0005",
            "sentence": "An epidemic of VL in Southern Sudan that emerged during the civil conflicts in the 1980s and 1990s is estimated to have killed more than 100,000 individuals [8,9], approximately 10 times the number of deaths from the 2014\u201315 West African Ebola virus infection outbreak [10].",
            "startOffset": 10189,
            "title": "About the disease and pathogen"
        },
        {
            "endOffset": 14061,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Overview of current efforts"
                }
            ],
            "secId": "sec0015",
            "sentence": "However, issues pertaining to standardization and control of the dose and strain identity, the occurrence of persistent lesions and the risk of disseminated leishmaniasis in immunocompromised individuals, limit the actual deployment of this approach.",
            "startOffset": 13811,
            "title": "Biological feasibility for vaccine development"
        },
        {
            "endOffset": 11704,
            "parents": [],
            "refoffsets": {
                "bib0245": {
                    "endOffset": 11703,
                    "startOffset": 11696
                },
                "bib0250": {
                    "endOffset": 11541,
                    "startOffset": 11537
                },
                "bib0255": {
                    "endOffset": 11703,
                    "startOffset": 11696
                }
            },
            "secId": "sec0005",
            "sentence": "Indoor residual spraying has been key to sand fly control in many areas, but there is concern about the emergence of dichlorodiphenyltrichloroethane (DDT) resistance, especially in highly endemic areas such as in Bihar state, India [13], where insecticide spraying or bed nets are difficult to sustain due to the large number of sand flies and potential reservoirs for parasite transmission [12,14].",
            "startOffset": 11305,
            "title": "About the disease and pathogen"
        },
        {
            "endOffset": 17819,
            "parents": [],
            "secId": "sec0030",
            "sentence": "The vast majority of these candidates are still in early stages of preclinical testing.",
            "startOffset": 17732,
            "title": "Status of vaccine R&D activities"
        },
        {
            "endOffset": 11918,
            "parents": [],
            "refoffsets": {
                "bib0200": {
                    "endOffset": 11917,
                    "startOffset": 11911
                },
                "bib0260": {
                    "endOffset": 11917,
                    "startOffset": 11911
                }
            },
            "secId": "sec0005",
            "sentence": "Dogs are significant reservoirs for L. major (a cause of CL in the Middle East and elsewhere), L. infantum (a cause of CL and VL in southern Europe, and elsewhere), and L. chagasi (a cause of VL in Brazil) [3,15].",
            "startOffset": 11705,
            "title": "About the disease and pathogen"
        },
        {
            "endOffset": 17498,
            "parents": [],
            "refoffsets": {
                "bib0245": {
                    "endOffset": 17497,
                    "startOffset": 17490
                },
                "bib0255": {
                    "endOffset": 17497,
                    "startOffset": 17490
                }
            },
            "secId": "sec0025",
            "sentence": "Although other recombinant protein based vaccines have been demonstrated to be reproducible, scalable, cost effective, and able to meet the current quality and regulatory requirements for vaccines, the need for the use of a potentially new adjuvant could pose an additional regulatory concern [12,14].",
            "startOffset": 17197,
            "title": "Technical and regulatory assessment"
        },
        {
            "endOffset": 16132,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Overview of current efforts"
                }
            ],
            "refoffsets": {
                "bib0310": {
                    "endOffset": 16131,
                    "startOffset": 16127
                }
            },
            "secId": "sec0020",
            "sentence": "Leishmania antigens that induce protective immune responses in mice, hamsters, and dogs, have been identified and various combinations of these antigens are being tested as recombinant proteins [25].",
            "startOffset": 15933,
            "title": "General approaches to vaccine development for this disease for low and middle income country markets"
        },
        {
            "endOffset": 20148,
            "parents": [],
            "refoffsets": {
                "bib0240": {
                    "endOffset": 20147,
                    "startOffset": 20137
                },
                "bib0305": {
                    "endOffset": 20147,
                    "startOffset": 20137
                },
                "bib0330": {
                    "endOffset": 20147,
                    "startOffset": 20137
                }
            },
            "secId": "sec0030",
            "sentence": "This trial then compared this formulation to the un-adjuvanted LEISH-F3 [11,24,29].",
            "startOffset": 20065,
            "title": "Status of vaccine R&D activities"
        },
        {
            "endOffset": 21536,
            "parents": [],
            "refoffsets": {
                "bib0310": {
                    "endOffset": 21535,
                    "startOffset": 21528
                },
                "bib0315": {
                    "endOffset": 21535,
                    "startOffset": 21528
                }
            },
            "secId": "sec0030",
            "sentence": "Here, immunomodulatory salivary proteins of the sand fly vectors (Phlebotomus and Lutzomyia spp.) are of particular interest [25,26].",
            "startOffset": 21403,
            "title": "Status of vaccine R&D activities"
        },
        {
            "endOffset": 20064,
            "parents": [],
            "secId": "sec0030",
            "sentence": "The LEISH-F3 vaccine is formulated with glucopyranosyl lipid A (GLA-SE, 2 \u03bcg or 5 \u03bcg), a stable emulsion of the novel Toll-like receptor 4 based adjuvant.",
            "startOffset": 19910,
            "title": "Status of vaccine R&D activities"
        },
        {
            "endOffset": 14306,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Overview of current efforts"
                }
            ],
            "refoffsets": {
                "bib0285": {
                    "endOffset": 14305,
                    "startOffset": 14301
                }
            },
            "secId": "sec0015",
            "sentence": "As an alternative to employing live Leishmania parasites, attempts have been made to use killed whole parasites together with the BCG vaccine, but so far this approach has not achieved significant success, in terms of levels of protection [20].",
            "startOffset": 14062,
            "title": "Biological feasibility for vaccine development"
        },
        {
            "endOffset": 19058,
            "parents": [],
            "secId": "sec0030",
            "sentence": "This new construct lacks a histidine tag at the N-terminus, which better complies with the regulatory agencies\u2019 preference of keeping recombinant molecules as close to their naturally occurring form as possible.",
            "startOffset": 18847,
            "title": "Status of vaccine R&D activities"
        },
        {
            "endOffset": 9610,
            "parents": [],
            "secId": "sec0005",
            "sentence": "Infected individuals present with fever, wasting, anaemia, hepatosplenomegaly, and a depressed immune response, leading to pancytopenia and superimposed infections.",
            "startOffset": 9446,
            "title": "About the disease and pathogen"
        },
        {
            "endOffset": 18846,
            "parents": [],
            "secId": "sec0030",
            "sentence": "Considering the early encouraging results of LEISH-F1, IDRI designed their new construct, LEISH-F2, and progressed it into phase I and a phase II clinical trials.",
            "startOffset": 18684,
            "title": "Status of vaccine R&D activities"
        },
        {
            "endOffset": 11304,
            "parents": [],
            "secId": "sec0005",
            "sentence": "In terms of the public health control or elimination of leishmaniasis, the major approach has relied on sand fly vector control.",
            "startOffset": 11176,
            "title": "About the disease and pathogen"
        },
        {
            "endOffset": 17731,
            "parents": [],
            "secId": "sec0030",
            "sentence": "Their delivery as DNA or directly as recombinant proteins has been examined.",
            "startOffset": 17655,
            "title": "Status of vaccine R&D activities"
        },
        {
            "endOffset": 12064,
            "parents": [],
            "secId": "sec0005",
            "sentence": "Ultimately, the development and delivery of a vaccine could represent one of the most cost effective means of controlling or eliminating CL or VL.",
            "startOffset": 11918,
            "title": "About the disease and pathogen"
        },
        {
            "endOffset": 20620,
            "parents": [],
            "secId": "sec0030",
            "sentence": "Other groups including the Sabin Vaccine Institute Product Development Partnership (Sabin PDP) are exploring prototype combination vaccines comprised of recombinant L. donovani NH36 expressed in either yeast or bacteria, together with a recombinant protein encoding one of several different sand fly salivary gland antigens.",
            "startOffset": 20296,
            "title": "Status of vaccine R&D activities"
        },
        {
            "endOffset": 19909,
            "parents": [],
            "refoffsets": {
                "bib0245": {
                    "endOffset": 19908,
                    "startOffset": 19898
                },
                "bib0305": {
                    "endOffset": 19908,
                    "startOffset": 19898
                },
                "bib0350": {
                    "endOffset": 19908,
                    "startOffset": 19898
                }
            },
            "secId": "sec0030",
            "sentence": "The LEISH-F3 candidate is made by fusing, in tandem, the open reading frames of nucleoside hydrolase (NH) from L. donovani and sterol 24-c-methyltransferase (SMT) from L. infantum [12,24,33].",
            "startOffset": 19718,
            "title": "Status of vaccine R&D activities"
        },
        {
            "endOffset": 16403,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Overview of current efforts"
                }
            ],
            "secId": "sec0020",
            "sentence": "Although vaccines targeting T cell-dependent immunity for protection have been more difficult to develop compared to those targeting antibody-mediated immunity, progress in the development of safe and effective adjuvants presents novel options for improved formulations.",
            "startOffset": 16133,
            "title": "General approaches to vaccine development for this disease for low and middle income country markets"
        },
        {
            "endOffset": 18684,
            "parents": [],
            "refoffsets": {
                "bib0245": {
                    "endOffset": 18683,
                    "startOffset": 18673
                },
                "bib0335": {
                    "endOffset": 18683,
                    "startOffset": 18673
                },
                "bib0340": {
                    "endOffset": 18683,
                    "startOffset": 18673
                }
            },
            "secId": "sec0030",
            "sentence": "Also, when used in conjunction with chemotherapy, the LEISH-F1 vaccine appeared to have shortened the time to cure [12,30,31].",
            "startOffset": 18558,
            "title": "Status of vaccine R&D activities"
        },
        {
            "endOffset": 13108,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Overview of current efforts"
                }
            ],
            "refoffsets": {
                "bib0245": {
                    "endOffset": 13107,
                    "startOffset": 13097
                },
                "bib0275": {
                    "endOffset": 13107,
                    "startOffset": 13097
                },
                "bib0280": {
                    "endOffset": 13107,
                    "startOffset": 13097
                }
            },
            "secId": "sec0015",
            "sentence": "A pivotal argument for the development of a vaccine for leishmaniasis is that the majority of people who recover from infection become immune [12,18,19].",
            "startOffset": 12955,
            "title": "Biological feasibility for vaccine development"
        },
        {
            "endOffset": 15067,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Overview of current efforts"
                }
            ],
            "refoffsets": {
                "bib0275": {
                    "endOffset": 15066,
                    "startOffset": 15059
                },
                "bib0300": {
                    "endOffset": 15066,
                    "startOffset": 15059
                }
            },
            "secId": "sec0015",
            "sentence": "Ideally an effective vaccine against leishmaniasis will elicit long-lasting immunity, thereby limiting chemotherapy usage, and involve a balanced TH1- and TH2-mediated immune response from vaccination [18,23].",
            "startOffset": 14858,
            "title": "Biological feasibility for vaccine development"
        },
        {
            "endOffset": 10593,
            "parents": [],
            "secId": "sec0005",
            "sentence": "CL, while not typically a life-threatening infection, is a cause of disfigurement and thus stigma, especially for girls and women.",
            "startOffset": 10463,
            "title": "About the disease and pathogen"
        },
        {
            "endOffset": 19206,
            "parents": [],
            "refoffsets": {
                "bib0245": {
                    "endOffset": 19205,
                    "startOffset": 19198
                },
                "bib0300": {
                    "endOffset": 19205,
                    "startOffset": 19198
                }
            },
            "secId": "sec0030",
            "sentence": "Moreover, Lys274, a potential proteolytic hot spot, was replaced with a glutamine residue to potentially improve the manufacturing process [12,23].",
            "startOffset": 19059,
            "title": "Status of vaccine R&D activities"
        },
        {
            "endOffset": 13286,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Overview of current efforts"
                }
            ],
            "refoffsets": {
                "bib0245": {
                    "endOffset": 13285,
                    "startOffset": 13278
                },
                "bib0255": {
                    "endOffset": 13285,
                    "startOffset": 13278
                }
            },
            "secId": "sec0015",
            "sentence": "Further proof of biological feasibility of vaccine development (at least for CL) is provided by an ancient practice that pre-dates modern vaccinology, \u201cleishmanization\u201d [12,14].",
            "startOffset": 13109,
            "title": "Biological feasibility for vaccine development"
        },
        {
            "endOffset": 14857,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Overview of current efforts"
                }
            ],
            "refoffsets": {
                "bib0255": {
                    "endOffset": 14856,
                    "startOffset": 14846
                },
                "bib0275": {
                    "endOffset": 14856,
                    "startOffset": 14846
                },
                "bib0295": {
                    "endOffset": 14856,
                    "startOffset": 14846
                }
            },
            "secId": "sec0015",
            "sentence": "There is currently no licensed vaccine against human leishmaniasis, and although several vaccines have advanced to clinical trials, most are still in early research and development (Table 1) [14,18,22].",
            "startOffset": 14655,
            "title": "Biological feasibility for vaccine development"
        },
        {
            "endOffset": 8520,
            "parents": [],
            "refoffsets": {
                "bib0205": {
                    "endOffset": 8519,
                    "startOffset": 8516
                }
            },
            "secId": "sec0005",
            "sentence": "The most recent estimates from the Global Burden of Disease Study (GBD) 2010 indicate that more than 50,000 annual deaths result from leishmaniasis and 3.3 million disability-adjusted life years (DALYs) are accrued, ranking leishmaniasis, along with schistosomiasis and hookworm infection, as those neglected tropical diseases (NTDs) with the highest disease burden [4].",
            "startOffset": 8150,
            "title": "About the disease and pathogen"
        },
        {
            "endOffset": 21402,
            "parents": [],
            "refoffsets": {
                "bib0310": {
                    "endOffset": 21401,
                    "startOffset": 21397
                }
            },
            "secId": "sec0030",
            "sentence": "Lastly, it is also critical to develop an effective delivery system and adjuvant in order to advance a Leishmania vaccine [25].",
            "startOffset": 21275,
            "title": "Status of vaccine R&D activities"
        },
        {
            "endOffset": 17654,
            "parents": [],
            "secId": "sec0030",
            "sentence": "Many different antigens have been explored for their use as candidate vaccines in preventative and therapeutic indications.",
            "startOffset": 17531,
            "title": "Status of vaccine R&D activities"
        },
        {
            "endOffset": 20846,
            "parents": [],
            "refoffsets": {
                "bib0315": {
                    "endOffset": 20845,
                    "startOffset": 20838
                },
                "bib0320": {
                    "endOffset": 20845,
                    "startOffset": 20838
                },
                "bib0325": {
                    "endOffset": 20845,
                    "startOffset": 20838
                }
            },
            "secId": "sec0030",
            "sentence": "The sand fly antigens were first developed in the laboratories of Jesus Valenzuela and Shaden Kamhawi at NIAID, NIH and shown to be effective in preventing infection, as well as eliciting a potent TH1 adjuvant effect [26\u201328].",
            "startOffset": 20621,
            "title": "Status of vaccine R&D activities"
        },
        {
            "endOffset": 10855,
            "parents": [],
            "refoffsets": {
                "bib0240": {
                    "endOffset": 10854,
                    "startOffset": 10850
                }
            },
            "secId": "sec0005",
            "sentence": "The disease has reached epidemic proportions because of the conflicts and public health breakdowns in Syria (where it sometimes known as \u201cAleppo evil\u201d), Iraq, Afghanistan and elsewhere in the Middle East and Central Asia, and is widespread in the Americas [11].",
            "startOffset": 10594,
            "title": "About the disease and pathogen"
        },
        {
            "endOffset": 22357,
            "parents": [],
            "secId": "sec0040",
            "sentence": "Several of the authors are investigators and patent holders on vaccines against hookworm and other neglected tropical diseases and are in part by grants to develop these diseases.",
            "startOffset": 22178,
            "title": "Conflict of interest"
        },
        {
            "endOffset": 12462,
            "parents": [],
            "refoffsets": {
                "bib0265": {
                    "endOffset": 12461,
                    "startOffset": 12457
                }
            },
            "secId": "sec0005",
            "sentence": "With regards to CL it has been estimated that using a vaccine that provides protection for 10 years at 70% efficacy within seven countries of Latin America: Bolivia, Brazil, Colombia, Ecuador, Mexico, Peru and Venezuela could prevent 41,000\u2013144,000 cases of CL, for less than what currently recommended treatments cost [16].",
            "startOffset": 12138,
            "title": "About the disease and pathogen"
        },
        {
            "endOffset": 20967,
            "parents": [],
            "secId": "sec0030",
            "sentence": "Although there is encouraging data from the animal models, the Sabin PDP is still in the research and development phase.",
            "startOffset": 20847,
            "title": "Status of vaccine R&D activities"
        },
        {
            "endOffset": 22158,
            "parents": [],
            "secId": "sec0035",
            "sentence": "New and increased financing from major funders will be critical to advance these candidate vaccines.",
            "startOffset": 22058,
            "title": "Likelihood for financing"
        },
        {
            "endOffset": 12137,
            "parents": [],
            "secId": "sec0005",
            "sentence": "At least two cost effectiveness modelling exercises have been published.",
            "startOffset": 12065,
            "title": "About the disease and pathogen"
        },
        {
            "endOffset": 9445,
            "parents": [],
            "secId": "sec0005",
            "sentence": "VL (also known as kala-azar) is the third most common parasitic cause of death, after malaria and infantile cryptosporidiosis.",
            "startOffset": 9319,
            "title": "About the disease and pathogen"
        },
        {
            "endOffset": 18362,
            "parents": [],
            "refoffsets": {
                "bib0245": {
                    "endOffset": 18361,
                    "startOffset": 18354
                },
                "bib0330": {
                    "endOffset": 18361,
                    "startOffset": 18354
                }
            },
            "secId": "sec0030",
            "sentence": "These proteins are present in many Leishmania species including L. donovani, and L. chagasi, which cause New World VL; and L. braziliensis, which causes both ML and CL in the New World [12,29].",
            "startOffset": 18169,
            "title": "Status of vaccine R&D activities"
        },
        {
            "endOffset": 16618,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Overview of current efforts"
                }
            ],
            "refoffsets": {
                "bib0315": {
                    "endOffset": 16617,
                    "startOffset": 16610
                },
                "bib0320": {
                    "endOffset": 16617,
                    "startOffset": 16610
                },
                "bib0325": {
                    "endOffset": 16617,
                    "startOffset": 16610
                }
            },
            "secId": "sec0020",
            "sentence": "Another vaccine approach targets the parasite vector, i.e. sand fly salivary proteins, which can exacerbate Leishmania infection [26\u201328].",
            "startOffset": 16481,
            "title": "General approaches to vaccine development for this disease for low and middle income country markets"
        },
        {
            "endOffset": 9920,
            "parents": [],
            "secId": "sec0005",
            "sentence": "Its sequelae, Post-Kala-azar Dermal Leishmaniasis (PKDL), is a chronic, disfiguring cutaneous condition associated with considerable morbidity and social stigma, in addition to likely contributing to Leishmania transmission.",
            "startOffset": 9696,
            "title": "About the disease and pathogen"
        },
        {
            "endOffset": 14489,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Overview of current efforts"
                }
            ],
            "secId": "sec0015",
            "sentence": "Many pre-clinical models including murine, canine, and hamster for both CL and VL have been developed and are used extensively for assessing vaccines and adjuvants for Leishmaniasis.",
            "startOffset": 14307,
            "title": "Biological feasibility for vaccine development"
        },
        {
            "endOffset": 21275,
            "parents": [],
            "refoffsets": {
                "bib0310": {
                    "endOffset": 21274,
                    "startOffset": 21267
                },
                "bib0355": {
                    "endOffset": 21274,
                    "startOffset": 21267
                }
            },
            "secId": "sec0030",
            "sentence": "Beyond the PDPs mentioned above, many other groups of investigators, including the European Multivalent Vaccine for Human Visceral Leishmaniasis (MeLeVaClin), are working on advancing recombinant protein-based, DNA-based, and heterologous prime-boost vaccine strategies for VL in pre-clinical models [25,34].",
            "startOffset": 20967,
            "title": "Status of vaccine R&D activities"
        },
        {
            "endOffset": 14655,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Overview of current efforts"
                }
            ],
            "refoffsets": {
                "bib0290": {
                    "endOffset": 14654,
                    "startOffset": 14650
                }
            },
            "secId": "sec0015",
            "sentence": "These models provide a wealth of information related to cellular immunity and have facilitated in vivo studies of the mechanism of action of numerous adjuvants [21].",
            "startOffset": 14490,
            "title": "Biological feasibility for vaccine development"
        },
        {
            "endOffset": 17046,
            "parents": [],
            "refoffsets": {
                "bib0255": {
                    "endOffset": 17045,
                    "startOffset": 17041
                }
            },
            "secId": "sec0025",
            "sentence": "The development of second generation vaccines against Leishmaniasis involves preparations that are more refined than their first generation whole cell based counterparts by using recombinant DNA technology to produce proteins, which are then adjuvanted in the final vaccine formulation, while third generation vaccines are DNA based and used in heterologous prime-boost vaccine regimens [14].",
            "startOffset": 16654,
            "title": "Technical and regulatory assessment"
        },
        {
            "endOffset": 7855,
            "parents": [],
            "secId": "sec0005",
            "sentence": "Leishmaniasis is caused by a protozoan parasite of the genus Leishmania, of which there are over 20 species that are pathogenic to humans.",
            "startOffset": 7717,
            "title": "About the disease and pathogen"
        },
        {
            "endOffset": 18032,
            "parents": [],
            "refoffsets": {
                "bib0245": {
                    "endOffset": 18031,
                    "startOffset": 18024
                },
                "bib0330": {
                    "endOffset": 18031,
                    "startOffset": 18024
                }
            },
            "secId": "sec0030",
            "sentence": "The first vaccine candidate to make it into phase I and II clinical trials was a polyprotein expressed in bacteria and known as LEISH-F1 from The Infectious Disease Research Institute (IDRI, Seattle, WA) [12,29].",
            "startOffset": 17820,
            "title": "Status of vaccine R&D activities"
        },
        {
            "endOffset": 20296,
            "parents": [],
            "refoffsets": {
                "bib0305": {
                    "endOffset": 20295,
                    "startOffset": 20288
                },
                "bib0350": {
                    "endOffset": 20295,
                    "startOffset": 20288
                }
            },
            "secId": "sec0030",
            "sentence": "This trial found LEISH-F3 to be safe, well tolerated and immunogenic in those groups receiving the stable emulsion, at either 2 \u03bcg or 5 \u03bcg [24,33].",
            "startOffset": 20149,
            "title": "Status of vaccine R&D activities"
        },
        {
            "endOffset": 17196,
            "parents": [],
            "secId": "sec0025",
            "sentence": "However, because no human DNA-based vaccines have as yet progressed to licensure, there is interest in pursuing recombinant protein based approaches.",
            "startOffset": 17047,
            "title": "Technical and regulatory assessment"
        },
        {
            "endOffset": 19592,
            "parents": [],
            "refoffsets": {
                "bib0245": {
                    "endOffset": 19591,
                    "startOffset": 19581
                },
                "bib0300": {
                    "endOffset": 19591,
                    "startOffset": 19581
                },
                "bib0345": {
                    "endOffset": 19591,
                    "startOffset": 19581
                }
            },
            "secId": "sec0030",
            "sentence": "Confirmation of immunogenicity and safety from the phase I trial propelled the clinical development to a phase II trial, enrolling adult and adolescent volunteers infected with CL, where the efficacy, safety, and immunogenicity of the therapeutic vaccine was studied after three administrations of LEISH-F2 (10 \u03bcg) + MPL-SE (25 \u03bcg) and was compared to standard chemotherapy [12,23,32].",
            "startOffset": 19207,
            "title": "Status of vaccine R&D activities"
        },
        {
            "endOffset": 13594,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Overview of current efforts"
                }
            ],
            "secId": "sec0015",
            "sentence": "Widely practiced in the Middle East and Central Asia, individuals were immunized using thorns or sharp instruments to introduce live (whole-cell) parasites to artificially simulate a cutaneous infection, in an unexposed site on the body so as to prevent the risk of facial lesions through natural infection.",
            "startOffset": 13287,
            "title": "Biological feasibility for vaccine development"
        },
        {
            "endOffset": 22057,
            "parents": [],
            "refoffsets": {
                "bib0360": {
                    "endOffset": 22056,
                    "startOffset": 22052
                }
            },
            "secId": "sec0035",
            "sentence": "According to the G-Finder, from 2007 to 2013, over US$66 million in funding was awarded for Leishmaniasis vaccine R&D (preventative and therapeutic), primarily from major public sector and philanthropic funders including the Bill & Melinda Gates Foundation, Carlos Slim Foundation, European Commission, German Federal Ministry of Education and Research (BMBF), Indian Council of Medical Research (ICMR), Institut Pasteur, and the U.S. National Institutes of Health (NIH), and Wellcome Trust [35].",
            "startOffset": 21561,
            "title": "Likelihood for financing"
        },
        {
            "endOffset": 10961,
            "parents": [],
            "secId": "sec0005",
            "sentence": "Chemotherapy is the main treatment for all three major forms of leishmaniasis, and is generally effective.",
            "startOffset": 10855,
            "title": "About the disease and pathogen"
        },
        {
            "endOffset": 15476,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Overview of current efforts"
                }
            ],
            "refoffsets": {
                "bib0245": {
                    "endOffset": 15475,
                    "startOffset": 15462
                },
                "bib0255": {
                    "endOffset": 15475,
                    "startOffset": 15462
                },
                "bib0275": {
                    "endOffset": 15475,
                    "startOffset": 15462
                },
                "bib0295": {
                    "endOffset": 15475,
                    "startOffset": 15462
                }
            },
            "secId": "sec0020",
            "sentence": "Since live, whole-cell Leishmanization strategies are no longer seen as a viable vaccine strategy due to safety concerns, vaccine development approaches have now evolved to killed, inactivated parasite vaccines, or even the insertion of suicidal cassettes directly into the Leishmania genome [12,14,18,22].",
            "startOffset": 15170,
            "title": "General approaches to vaccine development for this disease for low and middle income country markets"
        },
        {
            "endOffset": 12878,
            "parents": [],
            "secId": "sec0005",
            "sentence": "However, there is an urgent need to model CL and VL (as well as MCL) vaccines across a wide range of scenarios, including different levels of parasite transmission and parasite ecologies.",
            "startOffset": 12691,
            "title": "About the disease and pathogen"
        }
    ],
    "docId": "S0264410X16002899",
    "metadata": {
        "asjc": [
            "1313",
            "2400",
            "2725",
            "2739",
            "3400"
        ],
        "authors": [
            {
                "email": null,
                "first": "Portia M.",
                "initial": "P.M.",
                "last": "Gillespie"
            },
            {
                "email": null,
                "first": "Coreen M.",
                "initial": "C.M.",
                "last": "Beaumier"
            },
            {
                "email": null,
                "first": "Ulrich",
                "initial": "U.",
                "last": "Strych"
            },
            {
                "email": null,
                "first": "Tara",
                "initial": "T.",
                "last": "Hayward"
            },
            {
                "email": null,
                "first": "Peter J.",
                "initial": "P.J.",
                "last": "Hotez"
            },
            {
                "email": "bottazzi@bcm.edu",
                "first": "Maria Elena",
                "initial": "M.E.",
                "last": "Bottazzi"
            }
        ],
        "doi": "10.1016/j.vaccine.2015.12.071",
        "firstpage": "2992",
        "issn": "0264410X",
        "keywords": [
            "Leishmaniasis",
            "NTDs",
            "Neglected tropical diseases"
        ],
        "lastpage": "2995",
        "openaccess": "Full",
        "pub_year": 2016,
        "subjareas": [
            "BIOC",
            "IMMU",
            "MEDI",
            "VETE"
        ],
        "title": "Status of vaccine research and development of vaccines for leishmaniasis"
    }
}